Evidence map›Paper›PMID 39777952›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Design of Cell-Penetrating Domain Antibodies via a Genetically Encoded β-Lactam Amino Acid.

Johnathan D Rabb, Lucas E Kruse, Qing Lin

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Johnathan D RabbDepartment of Chemistry, State University of New York at Buffalo, Buffalo, New York, 14260-3000, United States.
Lucas E KruseDepartment of Chemistry, State University of New York at Buffalo, Buffalo, New York, 14260-3000, United States.
Qing LinDepartment of Chemistry, State University of New York at Buffalo, Buffalo, New York, 14260-3000, United States.ORCID 0000-0002-9196-5718

Funding

Development and Applications of Bioorthogonal Chemistry: Equipment SupplementR35GM130307 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Qing Lin · 2019 to 2026
$3.6M
Stopped flow spectrofluorometerS10RR015877 · NCRR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI STRAUBINGER, ROBERT M · 2002 to 2002
$218k
Division of Chemistry CHE-1904558Division of Chemistry CHE-2342675NCRR NIH HHS S10 RR015877NIGMS NIH HHS R35 GM130307NIGMS NIH HHS R35GM130307
6 · The paper itself

Abstract

Domain antibodies such as monobodies provide an attractive immunoglobin fold for evolving high-affinity protein binders targeting the intracellular proteins implicated in cell signalling. However, it remains a challenge to endow cell permeability to these small and versatile protein binders. Here, we report a streamlined approach combining orthogonal crosslinking afforded by a genetically encoded β-lactam-lysine (BeLaK) and genetic supercharging to generate cell-penetrating monobodies. When introduced to the N-terminal β-strand of a series of supercharged monobodies, BeLaK enabled efficient inter-strand crosslinking with the neighbouring lysine. Compared to its non-crosslinked counterpart, a BeLaK-crosslinked, +18-charged monobody exhibited enhanced thermostability and greater cellular uptake at 40 nM. Moreover, this structurally rigidified, supercharged monobody inhibited ERK1/2 phosphorylation in KYSE-520 esophageal cancer cell line at sub-micromolar concentration, indicating significant endosomal escape after endocytosis. Together, the discovery of this BeLaK-encoded, rigidified immunoglobin fold should facilitate the design of cell-penetrating monobodies targeting intracellular signalling proteins.

Indexed as

Amino Acidsbeta-LactamsCell-Penetrating PeptidesCell Line, TumorHumansAmino Acidsbeta-LactamsCell-Penetrating PeptidesDomain antibodyGenetic code expansionOrthogonal crosslinkingProximity-driven reactionβ-Lactam

Identifiers

PMID39777952
PMCPMC11850181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.